

REVIEW ARTICLE

Dan L. Longo, M.D., *Editor*

Treatment of Benzodiazepine Dependence

Michael Soyka, M.D.

TRADITIONALLY, VARIOUS TERMS HAVE BEEN USED TO DEFINE SUBSTANCE use–related disorders. These include “addiction,” “misuse” (in the *Diagnostic and Statistical Manual of Mental Disorders*, fourth edition [DSM-IV]¹), “harmful use” (in the *International Classification of Diseases, 10th Revision* [ICD-10]²), and “dependence.”³ Long-term intake of a drug can induce tolerance of the drug’s effects (i.e., increased amounts are needed to achieve intoxication, or the person experiences diminished effects with continued use⁴) and physical dependence. Addiction is defined by compulsive drug-seeking behavior or an intense desire to take a drug despite severe medical or social consequences. The DSM-IV and ICD-10 define misuse and harmful use, respectively, on the basis of various somatic or psychological consequences of substance use and define dependence on the basis of a cluster of somatic, psychological, and behavioral symptoms. According to the ICD-10, dependence is diagnosed if 3 or more of the following criteria were met in the previous year: a strong desire or compulsion to take the drug, difficulties in controlling drug use, withdrawal symptoms, evidence of tolerance, neglect of alternative pleasures or interests, and persistent drug use despite harmful consequences. The latest edition of the DSM (DSM-5)⁴ has abandoned the categorical distinction between abuse and dependence in favor of a dimensional approach, specifying 11 criteria for substance-use disorders, which range from mild (in patients meeting 2 or 3 criteria) to severe (in patients meeting 6 or more criteria).

Key elements of substance-use disorders are dose increases, tolerance of and craving for the drug’s effects, and loss of control. These diagnostic criteria and definitions are used for all classes of abused drugs, including prescription drugs such as benzodiazepines. However, the criteria may be less appropriate — or even problematic — in the case of mentally ill patients who use or are dependent on prescription drugs than in the case of mentally healthy persons who take drugs primarily for recreational purposes.

BENZODIAZEPINES

PHARMACOLOGIC FEATURES

The first benzodiazepine to be approved and introduced into clinical practice was chlordiazepoxide, which was introduced to the market in 1960.^{5,6} Today, approximately 35 benzodiazepine derivatives exist, 21 of which have been approved internationally (www.emcdda.europa.eu/publications/drug-profiles/benzodiazepine).⁶ They all bind to specific sites on the γ -aminobutyric acid (GABA) type A (GABA_A) receptor, increasing the receptor’s affinity for GABA, an inhibitory neurotransmitter (Fig. 1).

The greater affinity of GABA_A receptor for GABA increases the frequency of chloride-channel opening and potentiates the inhibitory effect of GABA in the central nervous system (CNS).⁷ Thus, benzodiazepines have no direct agonistic

From the Department of Psychiatry and Psychotherapy, Ludwig Maximilian University, Munich, and Medical Park Chiemseeblick, Bernau — both in Germany; and Privatlinik Meiringen, Meiringen, Switzerland. Address reprint requests to Dr. Soyka at Medical Park Chiemseeblick, Rasthausstrasse 25, 83233 Bernau, Germany, or at m.soyka@medicalpark.de.

N Engl J Med 2017;376:1147-57.

DOI: 10.1056/NEJMra1611832

Copyright © 2017 Massachusetts Medical Society.




Figure 1. Pharmacologic Characteristics of γ -Aminobutyric Acid Type A (GABA_A) Receptors.

The GABA_A receptor consists of five transmembrane glycoprotein subunits arranged around the central chloride channel. Each subunit is composed of four domains (domains 1 through 4); domain 2 (dark purple) is the part of the monomeric subunit that lines the chloride channel. Benzodiazepines increase the affinity of the GABA_A receptor for GABA and the likelihood that the receptor will open for chloride ions (light blue).

effect at the receptor. The GABA_A receptor is composed of various subunits (α_1 through α_6 , β_1 through β_3 , and γ_1 through γ_3) and variants, with hypnotic agents acting mainly through the α_1 subunit. GABA_A receptor function can be measured by means of positron-emission tomography with specific radiotracers.⁸

Pharmacologically, benzodiazepines cannot be clearly divided into those that are more anxiolytic and those that are more hypnotic. They have completely replaced older hypnotic agents, which were much less safe.⁵ Benzodiazepines are well absorbed and are highly protein-bound. They are metabolized in two basic pathways: glucuronide conjugation and microsomal oxidation. Some benzodiazepines already have a hydroxyl group (e.g., oxazepam and lorazepam) and consequently are metabolized directly by glucuronide conjugation; this group tends to have a shorter elimination half-life. However, the majority of benzodiazepines are demethylated or oxidized before conjugation and therefore have a longer half-life, with an associated risk of accumulation. Many benzodiazepines have pharma-

cologically active metabolites. Table 1 shows the half-lives of major benzodiazepines and relevant metabolites.^{6,9,10} Short-acting benzodiazepines are typically used as hypnotic agents (e.g., triazolam), and longer-acting benzodiazepines as anxiolytic or anticonvulsant agents (e.g., diazepam and clonazepam). There is modest evidence that benzodiazepines with a shorter half-life are associated with a greater risk of dependence.¹¹ Benzodiazepines also potentiate the sedative effects of opiates.⁶

CLINICAL USE

Benzodiazepines can be divided into anxiolytic agents and hypnotic agents on the basis of their clinical effects. In principle, however, all benzodiazepines have anxiolytic, hypnotic, muscle-relaxant, anticonvulsant, and amnesic effects. They are used as sedatives and to treat withdrawal symptoms, including alcohol withdrawal delirium.^{12,13} Benzodiazepines are relatively safe for short-term use (2 to 4 weeks), but their safety has not been established beyond that period,⁵ and dependence develops in approximately half

of patients who use benzodiazepines for longer than 1 month.¹¹ The risk of fatal intoxication by the use of a single drug is low.

SIDE EFFECTS

The main disadvantages and dose-dependent side effects of benzodiazepines are drowsiness, lethargy, fatigue, excessive sedation, stupor, “hangover effects” the next day, disturbances of concentration and attention, development of dependence, symptom rebound (i.e., recurrence of the original disorder, most commonly a sleep disorder) after discontinuation, and hypotonia and ataxia.¹⁴⁻¹⁷ Benzodiazepines can seriously impair driving ability and are associated with increased risks of traffic accidents, as well as falls and fractures.¹⁸⁻²⁰

Patients with myasthenia gravis, ataxia, the sleep apnea syndrome, chronic respiratory insufficiency, spinal and cerebellar ataxia, angle-closure glaucoma, or acute CNS-depressant intoxication should not receive treatment with this class of drugs. Paradoxical reactions are not uncommon in older patients (>65 years of age). Psychomotor retardation and cognitive dysfunction (memory loss, lack of concentration, and attention deficits) may occur.^{15,21,22} These drugs are not recommended for the treatment of insomnia, agitation, or delirium in the elderly and, if prescribed in this population, should be restricted to short-term use.²³ Their amnesic effects can result in memory gaps, especially at higher doses.¹⁴ An association of long-term benzodiazepine use with brain atrophy and dementia is controversial.¹⁷

BENZODIAZEPINE DEPENDENCE

NEURAL CORRELATES

The ventral tegmental area and nucleus accumbens are parts of the mesolimbic area of the brain; drugs that cause dopamine release in these areas generally have addictive potential.^{24,25} Neural projections to the prefrontal cortex represent important connections in the “addiction network.” The landmark studies by Tan et al.²⁶ showed that benzodiazepines also activate dopaminergic neurons in the ventral tegmental area by modulating GABA_A receptors in neighboring interneurons. The special relevance of α_1 -containing GABA_A receptors in the ventral tegmental area has been noted.²⁶ This information makes it clear that benzodiazepines act through

Table 1. Pharmacologic Classification and Half-Lives of Representative Benzodiazepines.*

Benzodiazepine	Substance Half-Life	Metabolite Half-Life
Hypnotic agents		
Long half-life: flurazepam	2–3	≤100
Intermediate half-life		
Flunitrazepam	10–30	20–30
Nitrazepam	18–30	—
Short half-life		
Brotizolam	3–6	3–6
Lormetazepam	8–14	8–14
Temazepam	7–14	4–15
Very short half-life: triazolam	1.5–5	—
Anxiolytic agents		
Long half-life		
Diazepam	24–48	≤200
Chlordiazepoxide	6–38	≤200
Clobazam	50	20
Clorazepate dipotassium	2–2.5	≤200
Medazepam	2–2.5	≤200
Prazepam	1–3	≤200
Short-to-intermediate half-life with active metabolites		
Lorazepam	2	—
Oxazepam	30	—
Alprazolam	12–15	1
Bromazepam	15	6

* Data on hypnotic agents are from Soyka,⁶ Benkert and Hippus,⁹ and Julien,¹⁰ and data on anxiolytic agents are from Benkert and Hippus.⁹ Dashes denote no active metabolite.

mechanisms similar to those of other drugs of abuse.

EPIDEMIOLOGIC FEATURES

The number of benzodiazepine prescriptions in the United States increased substantially from 1996 to 2013.²⁷ Deaths from overdose also increased, by a factor of more than 4 (from 0.58 to 3.07 deaths per 100,000 adults),²⁷ with a plateau after 2010, but nearly all the deaths involved the use of other substances in addition to benzodiazepines. Of patients receiving opioid maintenance therapy, approximately 46 to 71% use benzodiazepines^{28,29} (44% of German patients³⁰). These drugs enhance the respiratory-depressant

effects of opioids. On August 31, 2016, the Food and Drug Administration issued a drug-safety communication about serious risks, including death, when opioid pain or cough medicines are combined with benzodiazepines. The safety announcement warned that “health care professionals should limit prescribing opioid pain medicines with benzodiazepines . . . only to patients for whom alternative treatment options are inadequate.”³¹

In contrast to the prescribing pattern in the United States, the prescription of benzodiazepines in Europe has decreased substantially over the past few years. Nevertheless, benzodiazepines are still among the most frequently used psychopharmaceuticals worldwide. Long-term use is not synonymous with dependence. Recent data show that 35.8% of patients with new benzodiazepine prescriptions continue to use the drug after 3 months, with 15.2% using it for 1 year, and 4.9% for 8 years; 3% of the general population uses benzodiazepines for the long term.³² There is no standard definition of long-term use, but the most common definition is 6 to 12 months.³³ The risk of dependence on benzodiazepines or so-called z-drugs (nonbenzodiazepine drugs that have effects that are similar to those of benzodiazepines and most of which have generic names that start with the letter z [e.g., zolpidem, zopiclone, and zaleplon]) is significantly associated with a history of mental illness and with a large quantity of drugs taken.³⁴ The use of z-drugs has increased in Germany during the past 20 years, which is thought to have compensated in part for the decrease in benzodiazepine use.³⁵

According to an epidemiologic study,³⁶ 2.3 million people in Germany are dependent on medications; on the basis of DSM-IV criteria, the estimated overall prevalence of sedative abuse is 0.8% (among both men and women), and the prevalence of dependence is 1.4% among men and 1.3% among women. Benzodiazepine use tends to increase significantly with age.^{37,38} Petitjean et al.³⁸ reported that in Switzerland, 14.5% of patients were given benzodiazepines for more than 12 months. Neutel³⁹ found misuse of these drugs in 4.1% of the Canadian population. In the United States, Huang et al.⁴⁰ reported an abuse rate of 1.1% for sedatives and 1.0% for tranquilizers from this drug family.

A retrospective study of 2008 data in the United States showed that 5.2% of persons be-

tween the ages of 18 and 80 years used benzodiazepines, as did 8.7% of those between the ages of 65 and 80 years.³⁷ Women used benzodiazepines twice as frequently as men did. Long-term use was shown in a quarter of the sample. Moore et al.⁴¹ recommend stricter controls and suggest that benzodiazepines should be prescribed only by psychiatrists, who give fewer long-term prescriptions than other physicians; however, the issue is controversial. There is a striking discrepancy between the high prevalence of benzodiazepine dependence and the very low treatment rates, especially in addiction service centers.⁴²

CLINICAL FEATURES

In a study reported in 1961, Hollister et al. switched mentally healthy persons from chlordiazepoxide (300 to 600 mg) to placebo and found that sudden withdrawal resulted in seizures, delirium, and psychosis.⁴³ A special characteristic of benzodiazepines is that physical and mental dependence can develop in the absence of tolerance (low-dose dependence). Typical behavioral features of benzodiazepine dependence include doctor-shopping (i.e., seeking prescriptions from several different providers), obtaining prescriptions from different pharmacies, and overlapping prescriptions (Table 2).^{6,44-46} A recent study showed that clinical correlates of long-term benzodiazepine use are older age (>65 years), prescription by a psychiatrist, regular use, use of a high dose, and concomitant prescription of psychotropic drugs.⁴⁴

WITHDRAWAL SYMPTOMS

Symptoms of withdrawal after long-term benzodiazepine use usually develop faster with shorter-acting agents (within 2 to 3 days) than with longer-acting agents (within 5 to 10 days). Most withdrawal symptoms are associated with a state of brain hyperexcitability and can be divided into physical, psychological, and sensory symptoms. The mildest form of withdrawal is symptom rebound and is particularly common with withdrawal from benzodiazepines that are used for sleep disorders. The most common physical symptoms of withdrawal are muscle tension, weakness, spasms, pain, influenza-like symptoms (e.g., sweating and shivering), and “pins and needles.” The most common psychological withdrawal symptoms are anxiety and panic disorders, rest-

Table 2. Behavioral Correlates of Benzodiazepine Dependence.*

<p>People who have become dependent on therapeutic doses of benzodiazepines usually have several of the following characteristics:</p> <p>They have taken benzodiazepines in prescribed “therapeutic” (usually low) doses for months or years.</p> <p>They have gradually come to “need” benzodiazepines to carry out normal, day-to-day activities.</p> <p>They have continued to take benzodiazepines even though the original indication for the prescription has disappeared.</p> <p>Because of withdrawal symptoms, they have difficulty stopping use of the drug or reducing the dose.</p> <p>Those taking short-acting benzodiazepines have anxiety between doses or a craving for the next dose.</p> <p>They contact their doctor regularly to obtain repeat prescriptions.</p> <p>They become anxious if the next prescription is not readily available; they may carry their tablets around with them and may take an extra dose before an event that is anticipated to be stressful or before spending the night in a strange bed.</p> <p>They may have increased the dosage since the original prescription.</p> <p>They may have anxiety symptoms, panic attacks, agoraphobia, insomnia, depression, or increasing physical symptoms, despite continuing to take benzodiazepines.</p> <p>Doctor-shopping, emergency visits, and lost prescriptions are common.</p> <p>They use private prescriptions rather than those for which the cost would be reimbursed by health insurance.</p> <p>They take hypnotic agents during the day.</p>
--

* Data are from Soyka,⁶ Ashton,⁴⁵ and Soyka et al.⁴⁶

lessness and agitation, depression and mood swings, psychovegetative symptoms (e.g., tremor), reduced concentration, and sleep disturbances and nightmares.^{6,45-49} Appetite loss, tachycardia, blurred vision, and dry mouth may also be present, as may tinnitus, drowsiness, or derealization (a feeling that one’s surroundings are not real). Disorders of perception are relatively common and range from hyperacusis to photophobia to dysesthesia; these symptoms are not pathognomonic but are characteristic of benzodiazepine withdrawal. Seizures are quite common, especially if the agent is discontinued abruptly. Severe withdrawal symptoms include paranoid thoughts, hallucinations, depersonalization, and withdrawal delirium. Tables 3 and 4 provide an overview of withdrawal symptoms.^{6,45,47,49}

TREATMENT

TREATMENT OF WITHDRAWAL SYMPTOMS

Numerous studies and a Cochrane review have examined treatment of withdrawal.⁵⁰⁻⁵² The overall consensus is that benzodiazepines should be discontinued gradually over a period of several weeks (e.g., 4 to 6 weeks or more for diazepam doses >30 mg per day), to prevent seizures and avoid severe withdrawal symptoms. The withdrawal rate is often determined by a person’s

capacity to tolerate symptoms.⁵³ Recommendations range from reducing the initial benzodiazepine dose by 50% every week or so⁶ to reducing the daily dose by between 10% and 25% every 2 weeks.⁵³ A period of 4 to 6 or 4 to 8 weeks is suitable for withdrawal for most patients. If possible, prolonged reductions over a period of many months should be avoided in order to prevent the withdrawal treatment from becoming the patient’s “morbid focus.”¹⁵

Whether switching to a long-acting agent such as diazepam has fundamental advantages is unclear,⁴⁵ as is the question of whether hospital admission is required for a “blind reduction” (i.e., the patient is not told the exact dose). The use of several benzodiazepines should be converted to the use of one, preferably diazepam. Withdrawal from short-acting benzodiazepines is associated with higher dropout rates than withdrawal from longer-acting agents,^{6,51} but switching from a drug with a short half-life to one with a longer half-life is not associated with a better outcome.^{6,51} A relatively fixed withdrawal schedule with a precise duration of withdrawal treatment is recommended. Withdrawal is sometimes successful on an outpatient basis, but patients should be hospitalized for withdrawal from very high doses (a dose equivalent to ≥ 100 mg of diazepam daily).

Table 3. Clinical Symptoms and Complications of Benzodiazepine Withdrawal.*

Psychopathologic symptoms
Increased anxiety
Nervousness
Sleep disorders
Inner restlessness
Depressive symptoms
Irritability
Psychosis-like conditions, delirium
Depersonalization and derealization
Confusion
Vegetative symptoms
Trembling
Sweating
Nausea and vomiting
Motor agitation
Dyspnea
Increased heart rate
Elevated blood pressure
Headaches
Muscle tension
Neurologic and physical complications
Increased risk of seizures
Impairment of voluntary movements
Cognitive impairments
Impairment of memory
Pronounced perceptual impairments
Hyperacusis
Photophobia
Hypersomnia
Dysesthesia, kinesthetic disorders, muscle twitching and fasciculations

* Data are from Soyka,⁶ Ashton,⁴⁵ Lader and Kyriacou,⁴⁷ and Soyka and Batra.⁴⁹

In patients receiving opioid maintenance therapy, the dose of the opioid (e.g., methadone) should be kept stable throughout the benzodiazepine-reduction period and high enough to prevent symptoms of opioid withdrawal.²⁹ In cases of very high methadone doses (>150 mg per day) and frequent intoxicated presentations, the dose may be decreased.²⁹ The partial opioid agonist buprenorphine may carry a lower risk of benzodiazepine-related overdose than a full agonist

(e.g., methadone).^{29,54} Concurrent opioid detoxification is not recommended.⁵³ For some patients with concomitant benzodiazepine (or alcohol) use, the opioid is underdosed, and the opioid dose should be adjusted in these patients to relieve them from opioid-withdrawal symptoms.

Concomitant psychopharmacotherapy for benzodiazepine withdrawal is symptom-oriented and pragmatic. No medication is approved for the treatment of benzodiazepine-use disorders, and only a handful of relevant studies have been published. In patients with a coexisting psychiatric disorder (depression, anxiety, or schizophrenia), integrative therapy programs addressing both the underlying psychiatric condition and the benzodiazepine use are recommended.⁶

Only a few evidence-based treatment recommendations for pharmacotherapy are available.^{15,51} Symptomatic treatment includes antidepressant agents for depression and sleep problems, as well as mood stabilizers, especially carbamazepine (200 mg twice per day), although empirical evidence for these approaches is limited.^{5,47,51} Alternatives are nonbenzodiazepine anxiolytic agents, pregabalin, gabapentin, and beta-blockers^{6,55}; nonbenzodiazepine hypnotic agents are additional options. The abuse potential of GABAergic compounds such as pregabalin must be kept in mind.⁶ In the case of a chronic sleep disorder, recommended medications include such antidepressants as trazodone (at a dose of 25 to 150 mg per day), doxepin (10 to 150 mg per day), mirtazapine (7.5 to 30 mg per day), and trimipramine (10 to 150 mg per day), which should be given 1 to 3 hours before bedtime. These agents act mainly by antagonism at the histamine H₁ receptor and in part by anticholinergic actions and have no apparent abuse potential.⁴⁸ Alternatives are antihistaminergic agents, most of which are over-the-counter medications and include diphenhydramine (25 to 50 mg per day), doxylamine (25 to 50 mg per day), hydroxyzine (37.5 to 75 mg per day), and promethazine (25 to 200 mg per day).⁴⁸ Antidepressants that act primarily through serotonin-reuptake inhibition may be more suitable for patients with anxiety disorders. There is very modest evidence that melatonin improves sleep during benzodiazepine withdrawal, but its use remains largely experimental,^{47,56,57} as does the use of a slow subcutaneous infusion of the benzodiazepine antagonist flumazenil.⁵⁸ However, flumazenil use carries substantial med-

Table 4. Differential Diagnosis of Severe Benzodiazepine Withdrawal Syndromes or Intoxication.*

Alcohol, drug intoxication
Intoxication from other psychotropic substances (poly-drug use)
Hypoglycemia
Epilepsy
Cerebral hemorrhage
Cerebral infarction or brain injury
Myocardial infarction
Metabolic disturbances (e.g., thyroid disorder)
Psychosis, mania, or bipolar disorder
Alcohol-withdrawal delirium
Delirium in the elderly or in people with serious medical conditions
Agitation associated with psychopathy

* Data are from Soyka,⁶ Ashton,⁴⁵ Lader and Kyriacou,⁴⁷ and Soyka and Batra.⁴⁹

ical risks (e.g., seizures and psychoses).⁴⁷ A kind of “benzodiazepine substitution” with slow-onset, long-acting benzodiazepines has also been discussed,⁵⁹ but clinical evidence supporting its use is lacking.

PSYCHOTHERAPY FOR BENZODIAZEPINE DEPENDENCE

Minimal, brief interventions in primary care (provision of simple advice and informational leaflets) can facilitate an initial reduction in benzodiazepine use.^{60,61} A form of psychoeducation (i.e., provision of information on the effects and risks of long-term benzodiazepine use and possible alternatives) is often the initial step in treatment⁶⁰ but should be accompanied by other psychosocial interventions. Psychotherapeutic interventions for long-term benzodiazepine use have three goals: facilitate the withdrawal itself, facilitate further abstinence, and treat the underlying disorder.¹⁵

A number of evidence-based treatments are available for substance use in general.^{3,6,62} For example, techniques based on the transtheoretical model of Prochaska and Velicer,⁶³ such as motivational interviewing,⁶⁴ aim to induce behavioral changes by helping patients to balance and reconsider the advantages and disadvantages of drug use and motivating them to discontinue use. Higher self-efficacy expectations and a stronger

belief in the ability to quit are associated with a better outcome.⁶⁰ However, little evidence is available for psychosocial interventions in people with both severe illness and substance misuse,⁶⁵ and only a few experimental studies have investigated the efficacy of various therapies for prescription-drug dependence.^{66,67}

Cognitive behavioral therapy plays a strong role in treating benzodiazepine dependence.¹⁵ This therapeutic approach encompasses a number of techniques and combines elements of learning and behavioral theory. Cognitive behavioral therapy supports direct changes, addresses psychosocial stress factors, and provides training in coping and social skills and in the management of risk situations for benzodiazepine use (relapse prevention). The therapeutic components include social-competence training, relaxation techniques, training to overcome anxiety, and other behavioral-therapy approaches. These components focus on the reasons for and experiences with medication use and how to deal with risk situations and anxiety about meeting expectations and may also address pathogenic relationship patterns and unresolved mental conflicts. Cognitive behavioral therapy is the most widely used treatment for benzodiazepine dependence,⁶⁸ although a randomized, controlled trial showed that a 15-month period for tapering off benzodiazepines under controlled conditions without psychotherapy was superior to usual care alone or in combination with cognitive behavioral therapy.⁶⁷ In this study, short-term abstinence rates were 29 to 36%, but the 10-year abstinence rate was 59%.⁶⁹

Most meta-analyses of psychotherapy for substance-use disorders focus on alcohol or “illegal” drugs.⁷⁰ Psychological interventions with stepwise withdrawal are more effective than standard treatment (routine care),⁷¹ and short-term interventions performed by a family physician are helpful.⁶¹ A recent Cochrane analysis of psychosocial interventions for benzodiazepine use and dependence included 25 studies involving a total of 1666 people.⁵⁰ Two analyses were performed: one assessed the effectiveness of cognitive behavioral therapy plus benzodiazepine tapering versus tapering alone, and the other examined motivational interviewing versus treatment as usual. In brief, the analyses showed that cognitive behavioral therapy plus tapering is effective in reducing benzodiazepine use over a short

(3-month) period but not at 6 months or later and that there is insufficient evidence to support the use of motivational interviewing to reduce benzodiazepine use.

In general, the prognosis for patients who undergo withdrawal treatment for benzodiazepine dependence is fairly good.⁶ However, additional therapeutic approaches may be necessary, depending on whether there is underlying mental illness.⁴⁹ Motivational techniques are particularly useful during inpatient withdrawal treatment, whereas individual or group psychotherapeutic techniques are more useful during outpatient withdrawal treatment (e.g., for low-dose dependence). Other interventions include self-control training, cue exposure focusing on settings that may induce a craving for benzodiazepines, marital and family therapy, and less frequently, psychodynamically oriented treatments that focus on underlying conflicts and deficits in ego and personality development. Twelve-step treatments are frequently used in the United States, but they are less common in other parts of the world and are rarely used for benzodiazepine dependence.

Many treatments are eclectic, combining elements from various therapeutic approaches. Removal of self-medication as a rationalization for benzodiazepine use is of great relevance, especially for patients with a coexisting psychiatric disorder, such as anxiety disorder.⁷² More psychodynamically and psychoanalytically oriented therapies interpret medication dependence as a failed attempt at self-healing. These therapies address frustration, poor problem-solving strategies, and failure to tolerate negative emotions, all of which generally play a large role in drug dependence. Systemic therapies focus on the patient as the symptom carrier in a disturbed or dysfunctional family system and view addiction behavior as an attempt to regulate or control relationships. Psychoeducation includes provision of information on the effects and side effects of medications. In addition, self-control techniques are offered.

Nonpharmacologic interventions, especially stimulus control and sleep restriction, and to a lesser extent, sleep-hygiene education (which teaches patients to maintain a regular wake-and-sleep pattern, relax regularly during the week, and avoid stimulants and large meals before bedtime, among other things), are effective for in-

somnia in general.⁷³ They can also be used for sleep disorders associated with benzodiazepine withdrawal. One study showed that interventions such as sleep assessment, basic sleep hygiene (going to bed at the same time every night and avoiding naps), stimulus control (a quiet, comfortable bedroom, with no television viewing in bed and no lights), behavioral therapies such as sleep-restriction procedures (which force the patient's available sleep time into a fixed window), relaxation techniques such as progressive muscle relaxation, and cognitive treatments were effective for insomnia during long-term hypnotic-drug use, with results persisting for more than 1 year.⁷⁴

PREVENTION OF DEPENDENCE

A recent systematic review of patients' experiences with and perceptions of benzodiazepine use and use of other hypnotic agents identified themes of relevance for safer prescribing of these drugs, including the effects of insomnia and failed self-care strategies, among others.⁷⁵

Treatments lasting 2 to 3 months or more and marked dose increases should be avoided. In some patients, especially those with sleep disorders, intervals of treatment rather than continuous treatment may be advisable. Careful evaluation and reevaluation of the indication for treatment, adherence to dosing, avoidance of multiple prescriptions, and timely discontinuation of treatment (usually within 4 to 6 weeks) are essential. High-risk groups include persons who are alcohol- and drug-dependent, are chronically ill (particularly those with pain syndromes), or have chronic sleep disorders, personality disorders, or dysthymia. A critical issue is avoiding long-term prescriptions for older patients in the absence of a clear target symptom.

CONCLUSIONS FOR CLINICAL PRACTICE

There are clear and evidence-based treatment standards for medication withdrawal in benzodiazepine-dependent patients, even though they are a heterogeneous group. Table 5 presents a brief synopsis of treatment standards. In psychotherapy, good evidence exists for cognitive behavioral therapy and motivational approaches and for providing information and psychoeduca-

Table 5. Management of Benzodiazepine (BZD) Withdrawal.

Situation	Treatment Approach	Level of Evidence
Approach to BZD dependence in general	Gradual withdrawal over a period of several weeks or months	High
Use of several BZDs or sedatives	Switch to use of only one BZD for detoxification (diazepam)	Good
Choice of BZD for detoxification	Switch to a long-acting BZD (diazepam)	Low
BZD withdrawal in a patient receiving opioid maintenance therapy	Adjustment of opioid dose to prevent opioid withdrawal; switch to a partial agonist (buprenorphine)	Good for adjustment of opioid dose; moderate for switch to partial agonist
Concomitant pharmacotherapy for BZD withdrawal	Carbamazepine, 200 mg twice a day	Moderate
Sleep disorders	Antidepressants, antihistaminergic drugs, melatonin; improved sleep hygiene, sleep restriction, relaxation techniques	Moderate
Other drugs for treatment of withdrawal symptoms	Pregabalin, gabapentin, beta-blockers; flumazenil	Low for pregabalin, gabapentin, and beta-blockers; experimental for flumazenil
Psychotherapy	Cognitive behavioral therapy and other approaches	Good

tion. The prognosis with standard treatment is often fairly good. At the same time, from a clinical perspective, one does not have to attempt benzodiazepine withdrawal in every case. For patients without any motivation for withdrawal and those with a severe depressive episode or other major mental disorder, stabilization may be warranted before initiating withdrawal treatment. If patients have severe psychopathological symptoms, one can refrain from attempting withdrawal, given that the process often lasts for weeks and is sometimes distressing for the patient and the physician. Also, withdrawal can be difficult to achieve in some elderly persons

with long-term, low-dose dependence on hypnotic agents. If complete discontinuation of benzodiazepines is unlikely, one can attempt to reduce the dose as a harm-reduction strategy. Additional studies on adequate pharmacotherapy during and after benzodiazepine withdrawal and more evidence-based strategies clearly are required.

Dr. Soyka reports receiving consulting fees from Lundbeck, Indivior, and Novartis Pharmaceuticals, lecture fees from Mepha Pharma, Lundbeck, and Indivior, and travel support from Lundbeck. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

I thank Jacquie Klesing, E.L.S., for editing assistance with an earlier version of the manuscript.

REFERENCES

- Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
- The ICD-10 classification of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.
- Berglund M, Thelander S, Jonsson E. Treating alcohol and drug abuse: an evidence based review. Weinheim, Germany: Wiley-VCH Verlag, 2003.
- Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Association, 2013.
- Lader M. Benzodiazepines revisited — will we ever learn? *Addiction* 2011;106:2086-109.
- Soyka M. *Medikamentenabhängigkeit*. Stuttgart, Germany: Schattauer, 2015.
- Schofield PR, Darlison MG, Fujita N, et al. Sequence and functional expression of the GABA A receptor shows a ligand-gated receptor super-family. *Nature* 1987; 328:221-7.
- Frankle WG, Cho RY, Prasad KM, et al. In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients. *Am J Psychiatry* 2015;172:1148-59.
- Benkert O, Hippus H. *Kompendium der Psychiatrischen Pharmakotherapie*. 9th ed. Berlin: Springer, 2013.
- Julien RM. *Drogen und Psychopharmaka*. Heidelberg, Germany: Spektrum, 1997.
- de las Cuevas C, Sanz E, de la Fuente J. Benzodiazepines: more “behavioural” addiction than dependence. *Psychopharmacology (Berl)* 2003;167:297-303.
- Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. *Cochrane Database Syst Rev* 2010;3: CD005063.
- Baldwin DS, Aitchison K, Bateson A, et al. Benzodiazepines: risks and benefits — a reconsideration. *J Psychopharmacol* 2013;27:967-71.
- Buffett-Jerratt SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. *Curr Pharm Des* 2002;8:45-58.
- Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. *CNS Drugs* 2009;23:19-34.
- Mura T, Proust-Lima C, Akbaraly T, et al. Chronic use of benzodiazepines and latent cognitive decline in the elderly: results from the Three-City Study. *Eur Neuropsychopharmacol* 2013;23:212-23.
- Pariente A, de Gage SB, Moore N,

- Bégaud B. The benzodiazepine-dementia disorders link: current state of knowledge. *CNS Drugs* 2016;30:1-7.
18. Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel I, Mørland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. *Sleep Med* 2008;9:818-22.
19. Smink BE, Egberts AC, Lusthof KJ, Uges DR, de Gier JJ. The relationship between benzodiazepine use and traffic accidents: a systematic literature review. *CNS Drugs* 2010;24:639-53.
20. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? *Arch Intern Med* 2004;164:1567-72.
21. Koyama A, Steinman M, Ensrud K, Hillier TA, Yaffe K. Ten-year trajectory of potentially inappropriate medications in very old women: importance of cognitive status. *J Am Geriatr Soc* 2013;61:258-63.
22. Pisani MA, Murphy TE, Araujo KL, Slattum P, Van Ness PH, Inouye SK. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. *Crit Care Med* 2009;37:177-83.
23. Berryman SN, Jennings J, Ragsdale S, Lofton T, Huff DC, Rooker JS. Beers criteria for potentially inappropriate medication use in older adults. *Medsurg Nurs* 2012;21:129-32.
24. Lüscher C, Ungless MA. The mechanistic classification of addictive drugs. *PLoS Med* 2006;3(11):e437.
25. Saal D, Dong Y, Bonci A, Malenka RC. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. *Neuron* 2003;37:577-82.
26. Tan KR, Brown M, Laboué G, et al. Neural bases for addictive properties of benzodiazepines. *Nature* 2010;463:769-74.
27. Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. *Am J Public Health* 2016;106:686-8.
28. Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. *Drug Alcohol Depend* 2012;125:8-18.
29. Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. *Am J Addict* 2010;19:59-72.
30. Backmund M, Meyer K, Henkel C, Soyka M, Reimer J, Schütz CG. Co-consumption of benzodiazepines in heroin users, methadone-substituted and codeine-substituted patients. *J Addict Dis* 2005;24:17-29.
31. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Silver Spring, MD: Food and Drug Administration, 2016 (<https://www.fda.gov/Drugs/DrugSafety/ucm518473.htm>).
32. Takeshima N, Ogawa Y, Hayasaka Y, Furukawa TA. Continuation and discontinuation of benzodiazepine prescriptions: a cohort study based on a large claims database in Japan. *Psychiatry Res* 2016; 237:201-7.
33. Kurko TA, Saastamoinen LK, Tähkää S, et al. Long-term use of benzodiazepines: definitions, prevalence and usage patterns — a systematic review of register-based studies. *Eur Psychiatry* 2015; 30:1037-47.
34. Guerlais M, Grall-Bronnec M, Feuillet F, Gérardin M, Jolliet P, Victorri-Vigneau C. Dependence on prescription benzodiazepines and Z-drugs among young to middle-aged patients in France. *Subst Use Misuse* 2015;50:320-7.
35. Lohse MJ, Müller-Oerlinghausen MJ. Hypnotika und Sedativa. In: Schwabe U, Paffrath D, eds. *Arzneiverordnungs-Report 2013*. Heidelberg, Germany: Springer, 2013: 641-55.
36. Pabst A, Kraus L, Gomes de Matos E, Piontek D. Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012. *Sucht* 2013;59:321-31.
37. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. *JAMA Psychiatry* 2015;72:136-42.
38. Petitjean S, Ladewig D, Meier CR, Amrein R, Wiesbeck GA. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. *Int Clin Psychopharmacol* 2007;22:292-8.
39. Neutel CI. The epidemiology of long-term benzodiazepine use. *Int Rev Psychiatry* 2005;17:189-97.
40. Huang B, Dawson DA, Stinson FS, et al. Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: results of the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry* 2006;67:1062-73.
41. Moore N, Pariente A, Bégaud B. Why are benzodiazepines not yet controlled substances? *JAMA Psychiatry* 2015;72: 110-1.
42. Soyka M, Queri S, Küfner H, Rösner S. Where are the 1.9 million patients dependent on legal drugs hiding? *Nervenarzt* 2005;76:72-7. (In German.)
43. Hollister LE, Motzenbecker FP, Degan RO. Withdrawal reactions from chlorthalidazepoxide ("Librium"). *Psychopharmacologia* 1961;2:63-8.
44. Okumura Y, Shimizu S, Matsumoto T. Prevalence, prescribed quantities, and trajectory of multiple prescriber episodes for benzodiazepines: a 2-year cohort study. *Drug Alcohol Depend* 2016;158:118-25.
45. Ashton H. Benzodiazepine abuse. In: Caan W, de Bellerocche J, eds. *Drink, drugs and dependence: from science to clinical practice*. London: Routledge, 2002:197-212.
46. Soyka M, Steinberg R, Vollmer M. Withdrawal phenomena in stepwise withdrawal of benzodiazepines. *Nervenarzt* 1988;59:744-8. (In German.)
47. Lader M, Kyriacou A. Withdrawing benzodiazepines in patients with anxiety disorders. *Curr Psychiatry Rep* 2016;18:8.
48. Nissen C, Frase L, Hajak G, Wetter TC. Hypnotics — state of the science. *Nervenarzt* 2014;85:67-76. (In German.)
49. Soyka M, Batra A. Benzodiazepin-Abhängigkeit. In: Vorderholzer U, Hohagen F, eds. *Therapie psychischer Erkrankungen* State of the Art. Munich, Germany: Urban and Fischer, 2014:55-62.
50. Darker CD, Sweeney BP, Barry JM, Farrell MF, Donnelly-Swift E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. *Cochrane Database Syst Rev* 2015;5:CD009652.
51. Lader M. Benzodiazepine harm: how can it be reduced? *Br J Clin Pharmacol* 2014;77:295-301.
52. Diaper AM, Law FD, Melichar JK. Pharmacological strategies for detoxification. *Br J Clin Pharmacol* 2014;77:302-14.
53. Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health (England), Scottish Government, Welsh Assembly Government, Northern Ireland Executive, 2007 (http://www.nta.nhs.uk/uploads/clinical_guidelines_2007.pdf).
54. Nielsen S, Dietze P, Lee N, Dunlop A, Taylor D. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. *Addiction* 2007;102:616-22.
55. Mariani JJ, Malcolm RJ, Mamezur AK, et al. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. *Am J Drug Alcohol Abuse* 2016;42: 333-40.
56. Baandrup L, Fagerlund B, Jennum P, et al. Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial — the SMART trial protocol. *BMC Psychiatry* 2011;11: 160.
57. Baandrup L, Glenthøj BY, Jennum PJ. Objective and subjective sleep quality: melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. *Psychiatry Res* 2016;240:163-9.
58. Faccini M, Leone R, Opi S, et al. Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases. *J Psychopharmacol* 2016;30:1047-53.
59. Liebrez M, Boesch L, Stohler R, Caflisch C. Agonist substitution — a treatment alternative for high-dose benzo-

- diazepine-dependent patients? *Addiction* 2010;105:1870-4.
60. Ten Wolde GB, Dijkstra A, van Empelen P, van den Hout W, Neven AK, Zitman F. Long-term effectiveness of computer-generated tailored patient education on benzodiazepines: a randomized controlled trial. *Addiction* 2008;103:662-70.
61. Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. *Br J Gen Pract* 2011;61(590):e573-e578.
62. Lingford-Hughes AR, Welch S, Peters L, Nutt DJ. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. *J Psychopharmacol* 2012;26:899-952.
63. Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. *Am J Health Promot* 1997;12:38-48.
64. Miller WR, Rollnick S. *Motivational interviewing: helping people change*. 3rd ed. New York: Guilford, 2012.
65. Hunt GE, Siegfried N, Morley K, Sitharthan T, Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. *Cochrane Database Syst Rev* 2013;10:CD001088.
66. Oude Voshaar RC, Gorgels WJ, Mol AJ, et al. Long-term outcome of two forms of randomised benzodiazepine discontinuation. *Br J Psychiatry* 2006;188:188-9.
67. Voshaar RC, Gorgels WJ, Mol AJ, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. *Br J Psychiatry* 2003;182:498-504.
68. Otto C, Crackau B, Löhrmann I, et al. Brief intervention in general hospital for problematic prescription drug use: 12-month outcome. *Drug Alcohol Depend* 2009;105:221-6.
69. de Gier NA, Gorgels WJ, Lucassen PL, Oude Voshaar R, Mulder J, Zitman F. Discontinuation of long-term benzodiazepine use: 10-year follow-up. *Fam Pract* 2011; 28:253-9.
70. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. *Am J Psychiatry* 2008;165:179-87.
71. Parr JM, Kavanagh DJ, Cahill L, Mitchell G, McD Young R. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. *Addiction* 2009;104:13-24.
72. Baillie AL, Sannibale C. Anxiety and drug and alcohol problems. In: Baker A, Velleman R, eds. *Mental health and drug and alcohol problems*. London: Routledge, 2007:197-217.
73. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. *Am J Psychiatry* 1994;151:1172-80.
74. Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M. Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. *Health Technol Assess* 2004;8:iii-iv, 1-68.
75. Sirdifield C, Chipchase SY, Owen S, Siriwardena AN. A systematic review and meta-synthesis of patients' experiences and perceptions of seeking and using benzodiazepines and Z-drugs: towards safer prescribing. *Patient* 2017;10:1-15.

Copyright © 2017 Massachusetts Medical Society.

IMAGES IN CLINICAL MEDICINE

The *Journal* welcomes consideration of new submissions for Images in Clinical Medicine. Instructions for authors and procedures for submissions can be found on the *Journal's* website at NEJM.org. At the discretion of the editor, images that are accepted for publication may appear in the print version of the *Journal*, the electronic version, or both.